The ADC momentum has continued to dominate the oncology field throughout 2023, with the long-awaited approval of ImmunoGen’s ELAHERE – the 9^th ADC to be approved in just three years. To add to the excitement, this incredible breakthrough is the first ADC for platinum-resistant ovarian cancer, proving their potential for treatments beyond breast cancer.

Whether you have just ventured into the ADC space or are an ADC guru, the 14^th World ADC San Diego has got you covered. Accompanying you from early discovery to late-stage manufacturing and regulatory challenges, this meeting has been designed with one aim in mind: to maximize the therapeutic window of your ADC, and propel ADCs to become life-changing, front-line treatments for oncology patients.